Variable
Age (years), mean ± SD 46.2 ± 16.2
Sex, n (%) Female 6 (28.6)
Male 15 (71.4)
Length of hospital stay (days), median (IQR) 31 (25–46)
Indications for tigecycline, n (%) Pneumonia 6 (28.6)
Agranulocytosis 5 (23.8)
Multiple organ failure 3 (14.3)
Sepsis 2 (9.5)
Major surgery-related infection 2 (9.5)
Mixed infections in more than one part 1 (4.8)
Intra-abdominal infection 1 (4.8)
Septicemia 1 (4.8)
Loading dose of tigecycline, n (%) 100 mg 11 (52.4)
400 mg 1 (4.8)
None 9 (42.9)
Maintenance dose of tigecycline, n (%) 100 mg q12h 2 (9.5)
50 mg q12h 16 (76.2)
100 mg q12h and 50 mg q12h 3 (14.3)
Duration of tigecycline use (days), median (IQR) 11 (5–13)
Total dose (mg), median (IQR) 1200 (850–1650)
Time from tigecycline use to symptom onset (days), mean ± SD 7.2 ± 4.2
Presenting symptoms, n (%) Abdominal pain/discomfort/nausea/vomiting 16 (76.2)
None 5 (23.8)
AP severity, n (%) Mild 21 (100)
Modified CT severity score, median (IQR) 2 (0–2)
Amylase after tigecycline use (U/L), mean ± SD 135.8 ± 57.8
Lipase after tigecycline use (U/L), mean ± SD 347.1 ± 221.8
Time to symptom relief (days), mean ± SD 3.6 ± 1.9
Time to enzyme recovery (days), mean ± SD 7.1 ± 3.6
Naranjo score, mean ± SD 7.2 ± 1.5